Latest Regulatory Filings News

Immutep Limited reveals promising Phase II results from its AIPAC-003 trial, establishing 30 mg as the optimal biological dose of eftilagimod alfa combined with paclitaxel in metastatic breast cancer patients.

Ovanti Limited’s U.S. BNPL arm, Flote, has signed a Letter of Intent with Nasdaq-listed Miluna Acquisition Corp for a $300 million valuation, aiming for a Nasdaq listing while preserving Ovanti’s majority ownership.

C29 Metals has explained a delayed filing of a director interest notice as an isolated administrative oversight, reaffirming its compliance policies.

Elementos Limited has issued 17.5 million shares at 28 cents each as part of a strategic placement, with further shares planned for January 2026, positioning itself to capitalize on growing tin demand.

Coronado Global Resources has finalized its financial support agreement with Stanwell Corporation, cementing previously disclosed terms and providing clarity on its capital position.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

EMVision Medical Devices has begun a pivotal aeromedical study with the Royal Flying Doctor Service to test its portable First Responder brain scanner in remote emergency settings. The trial aims to validate device usability and workflow integration ahead of commercial rollout.

ASX Compliance has flagged Rent.com.au Limited for a late filing of a director’s interest change, raising questions about the company’s disclosure controls and compliance with listing rules.

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Metcash Limited has responded to an ASX query regarding the late filing of a director’s interest notice, attributing the delay to an administrative oversight and outlining plans to enhance compliance processes.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.